Why did LIXT's EPS remain flat in recent quarters?

The EPS of LIXT has remained flat in recent quarters due to a combination of factors:

1. **Revenue Growth**: The lack of revenue data in recent quarters makes it difficult to determine if the company's revenue is growing, which could be a contributing factor to the flat EPS. Without revenue growth, it may be challenging for the company to increase its earnings per share.
2. **Operating Expenses**: The company's focus on clinical trials and preclinical research, as indicated by the research and development costs, could be a significant expense that affects the net income and, consequently, the EPS. If the company has been able to manage its expenses effectively despite these costs, it could explain the flat EPS.
3. **Financial Strategy**: The company's financial statements suggest a need for additional capital to continue operations, which implies that a significant portion of the funds may be allocated towards raising capital rather than increasing earnings. This could also impact the EPS if the additional capital is not generating sufficient returns.
4. **Market Conditions**: The broader biotech market conditions, including industry-wide pressures and market fluctuations, could also impact the company's financial performance. Lixte Biotechnology Holdings, Inc. is facing challenges common to the biotech sector, such as potential delisting due to non-compliance with Nasdaq's requirements.

In conclusion, the flat EPS of LIXT in recent quarters can be attributed to a combination of factors including lack of revenue growth, high operating expenses, need for additional capital, and challenging market conditions.